GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the company and its collaborators delivered an oral presentation and two posters at the 2012 American Society of Hematology (ASH) Annual Meeting and Exposition. The oral presentation, which was given on December 9 at the meeting’s venue at the Georgia World Congress Center in Atlanta, highlighted data from GMI’s lead program GMI-1070, which is now partnered with Pfizer. The posters highlighted data from GMI’s E-selectin antagonist program, which the company is developing to treat acute myeloid leukemia (AML) and other cancers.
